The aim of this systematic review was to answer the question: What are the treatments
available for bisphosphonate-related osteonecrosis of the jaws (BRONJ) and their …

The introduction of imatinib mesylate (IM) has revolutionized the treatment of chronic
myeloid leukemia (CML). Although experience is too limited to permit evidence-based …

Abstract α, α-Bisphosphonates (BPs) are well established in the treatment of bone diseases
such as osteoporosis and Paget's disease. Their successful application originates from their …

We present current knowledge of bisphosphonate-associated osteonecrosis, a new oral
complication in oncology. It was first described in 2003, and hundreds of cases have been …

A prospective study was performed in 80 patients receiving bisphosphonates in order to
determine frequency of occurrence, risk factors, clinical presentation, radiology, pathology …

Bisphosphonates are the standard of care in the treatment of malignant bone diseases,
because of their ability to inhibit osteoclast-mediated bone destruction. We review here …

For patients with malignant disease taking bisphosphonates and denosumab, the incidence
of medication-related osteonecrosis of the jaw (MRONJ) is up to 15% in contrast to 0.01% in …

Imatinib mesylate (imatinib), a competitive inhibitor of the BCR-ABL tyrosine kinase, is highly
effective against chronic myelogenous leukemia (CML) cells. However, because 20–30% of …

Despite the remarkable results achieved with imatinib for the treatment of chronic myeloid
leukaemia, the emergence of resistance to this tyrosine kinase inhibitor has become a …

The biological activity and natural occurrence of the aminophosphonic acids were described
half a century ago. Since then the chemistry and biology of this class of compounds have …